BIOCON / Q4-FY24 / claim-ledger

Audit the questions that mattered.

Biocon · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

WatchQ4-FY24 · 2024-05-15Back to quarter ↗

Questions audited

Answered directly

46%

Numeric claims

Consistency

—

Question ledger

What was answered, and how?

Damayanti Kerai · HSBC

partial

Growth headroom and trajectory for commercial biosimilars in U.S.

We're seeing some very robust market share increases... sustained demand in volume... new product launches... the major impact would be seen in fiscal 2026.

Damayanti Kerai · HSBC

partial

Progress on market access and payer coverage for adalimumab.

We don't really see the market opening up in calendar 2024, but we'll see it begin to open up more materially in 2025... we are aggressively pursuing these opportunities.

Jainil Shah · JM Financial

direct

Will Biocon be in first wave of denosumab launches?

We are in a good position to make the filings in the next few months, and we'll be the first cohort that can launch in the U.S. and Europe as well.

Jainil Shah · JM Financial

direct

Timelines for denosumab and Stelara approvals and risks.

Regular cycle is about 12 months for the FDA and about 15 months with the clock stop for EMA. So that will be standard as expected for all the molecules.

Jainil Shah · JM Financial

partial

CapEx plans for next 2-3 years.

CapEx will taper down, calibrate down from recent levels, but we will be maintaining the necessary investments to support the capacities...

Jainil Shah · JM Financial

evasive

Growth guidance and number of launches in generics business.

I cannot give you exact number of products, but needless to say, our portfolio continues to be limited... these are differentiated, high-value products.

Surya Patra · Phillip Capital

evasive

Revenue growth outlook for biosimilars in FY25 given price competition.

We would expect that growth momentum to continue during fiscal 2024... I don't quite see the market starting point as you describe.

Surya Patra · Phillip Capital

partial

Is Humira losing share to other biosimilars, shrinking opportunity?

2023 essentially was where the innovator continued to hold more than 98% of the market... meaningful progress on the biosimilars will only happen in 2025.

Surya Patra · Phillip Capital

partial

Status of marketing arrangement with Viatris and R&D spend run rate.

The marketing arrangements with Viatris have now all successfully completed... there are no marketing arrangements left... R&D... calibration down from previous levels.

Neha Manpuria · Bank of America

partial

Risk to Biocon's Humira share from private label launches gaining traction.

That does not leave all the market out for Biocon. The market is open in the commercial, in the Medicare, in the Medicaid business.

Neha Manpuria · Bank of America

evasive

Net debt reduction plan and avenues for Biocon and BBL in next year.

We have bank opportunities, we have equity opportunities, we have hybrid opportunities... I can't give any specific quantitative guidance on that.

Nitin Agarwal · DAM Capital

partial

Status of GLP-1 approval in U.S. market.

The file is under review with the FDA... we expect liraglutide to meaningfully start contributing to the growth from FY 2026.